ANI Pharmaceuticals Q4 revenue up 39.7% YoY; issues 2024 guidance with Cortrophin Gel growth 52-61%

ANI PHARMACEUTICALS INC

2023-FY EPS reported $0.85 revenue$486,816,000

Q4 net revenues $131.7M (+39.7% YoY); GAAP diluted EPS $0.04; adjusted non-GAAP diluted EPS $1.00.
Rare Disease (Cortrophin Gel) Q4 revenue $41.7M (+137.3% YoY) with record new patient starts and prescribers.
Full-year 2023 net revenue $486.8M, adjusted EBITDA $133.8M, operating cash flow $119.0M.
2024 guidance: net revenue $520-542M, Cortrophin Gel $170-180M, adjusted EBITDA $135-145M, adjusted EPS $4.26-$4.67.
Generics segment revenue $71.8M (+23.8% YoY); 11 new products launched in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ANI PHARMACEUTICALS INC reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $131.7 million, net income $0.7 million, EPS $0.04. Guidance initiated.

Period: the fourth quarter and fiscal year ended December 31, 2023
Revenue: $131.7 million
Net income: $0.7 million
EPS: $0.04
Guidance: initiated
Result: reported results

Exact text from the filing

ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance • Generated quarterly net revenues of $131.7 million, representing year-over-year growth of 39.7%, net income to common shareholders of $0.7 million, GAAP diluted earnings per share of $0.04

View on SEC.gov

Browse all earnings releases →

ANI PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001023024-24-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.